Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts

Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts

<p>A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in preme...

Bibliografski detalji
Glavni autori:	Ge, W, Clendenen, TV, Afanasyeva, Y, Koenig, KL, Agnoli, C, Brinton, LA, Dorgan, JF, Eliassen, AH, Falk, RT, Hallmans, G, Hankinson, SE, Hoffman-Bolton, J, Key, TJ, Krogh, V, Nichols, HB, Sandler, DP, Schoemaker, MJ, Sluss, PM, Sund, M, Swerdlow, AJ, Visvanathan, K, Liu, M, Zeleniuch-Jacquotte, A
Format:	Journal article
Izdano:	Wiley 2018

Slični predmeti

Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
od: Tess V. Clendenen, i dr.
Izdano: (2019-03-01)

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts
od: Jung, S, i dr.
Izdano: (2017)

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
od: Fortner, RT, i dr.
Izdano: (2017)

Temporal reproducibility of IgG and IgM autoantibodies in serum from healthy women
od: T. V. Clendenen, i dr.
Izdano: (2022-04-01)

Genetic Polymorphisms in Vitamin D Metabolism and Signaling Genes and Risk of Breast Cancer: A Nested Case-Control Study.
od: Tess V Clendenen, i dr.
Izdano: (2015-01-01)

Temporal reliability of cytokines and growth factors in EDTA plasma
od: Marrangoni Adele M, i dr.
Izdano: (2010-11-01)

Free estradiol and breast cancer risk in postmenopausal women: Comparison of measured and calculated values
od: Key, T, i dr.
Izdano: (2003)

Genotyping of Single Nucleotide Polymorphisms in DNA Isolated from Serum Using Sequenom MassARRAY Technology.
od: Tess V Clendenen, i dr.
Izdano: (2015-01-01)

Serum Taurine and Stroke Risk in Women: A Prospective, Nested Case-Control Study.
od: Fen Wu, i dr.
Izdano: (2016-01-01)

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.
od: Key, T, i dr.
Izdano: (2003)

Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
od: Clendenen, T, i dr.
Izdano: (2019)

Circulating soluble Fas levels and risk of ovarian cancer
od: Krogh Vittorio, i dr.
Izdano: (2003-12-01)

Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies.
od: Key, T, i dr.
Izdano: (2013)

Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women
od: Jung, S, i dr.
Izdano: (2017)

The Premenopausal Breast Cancer Collaboration: A pooling project of studies participating in the National Cancer Institute Cohort Consortium
od: Nichols, HB, i dr.
Izdano: (2017)

Goodness-of-fit two-phase sampling designs for time-to-event outcomes: a simulation study based on New York University Women’s Health Study for breast cancer
od: Myeonggyun Lee, i dr.
Izdano: (2023-05-01)

Persistent Mullerian Duct Syndrome with Malignant Conversion of Mullerian Remnant
od: Abhilasha Jain, i dr.
Izdano: (2022-05-01)

Adult weight change and premenopausal breast cancer risk: a prospective pooled analysis of data from 628,463 women
od: Schoemaker, MJ, i dr.
Izdano: (2020)

Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression
od: Richard L. Cate
Izdano: (2022-06-01)

Familial müllerian agenesis
od: F Tiker, i dr.
Izdano: (2000-10-01)

Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors
od: Mitra Heidarpour, i dr.
Izdano: (2014-01-01)

Association of body mass index and age with subsequent breast cancer risk in premenopausal women
od: Premenopausal Breast Cancer Collaborative Group, i dr.
Izdano: (2018)

Association of body mass index and age with subsequent breast cancer risk in premenopausal women
od: Schoemaker, MJ, i dr.
Izdano: (2018)

Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case–control study in the Northern Sweden Maternity Cohort
od: Renée T. Fortner, i dr.
Izdano: (2017-07-01)

Persistent mullerian duct syndrome
od: Renu Divya, i dr.
Izdano: (2010-01-01)

Persistent mullerian duct syndrome
od: Divya Renu, i dr.
Izdano: (2010-01-01)

Frequency of Mullerian Duct Abnormalities
od: Humaira Rani
Izdano: (2009-06-01)

Diagnosis and treatment of müllerian malformations
od: Itana de Mattos Pinto e Passos, i dr.
Izdano: (2020-03-01)

The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis
od: Shin Young Kim, i dr.
Izdano: (2018-01-01)

Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies
od: Nichols, HB, i dr.
Izdano: (2018)

Müllerian Agenesis Masquerading as Secondary Amenorrhea
od: Gloria Tavera, i dr.
Izdano: (2018-01-01)

Mullerian anomalies: revisiting imaging and classification
od: Rashmi Dixit, i dr.
Izdano: (2025-02-01)

Extragenital Müllerian Adenosarcoma in the Pouch of Douglas
od: Ateş Karateke, i dr.
Izdano: (2014-03-01)

Mullerian Adenosarcoma of the Uterus with Sarcomatous Overgrowth
od: Reecha Singh, i dr.
Izdano: (2010-01-01)

Benign Retroperitoneal Cyst of Mullerian Type
od: Jay Yohendran, i dr.
Izdano: (2004-10-01)

Diabetes Mellitus With Renal and Müllerian Anomalies
od: Khushboo Agarwal, MBBS, MD, i dr.
Izdano: (2022-01-01)

Ovarian malposition – Mullerian anomalies revisited
od: Ahmet Helvacioglu, i dr.
Izdano: (2010-04-01)

Mullerian Agenesis Associated with Turner’s Syndrome
od: PADMANABHAN ELAMPARIDHI, i dr.
Izdano: (2017-02-01)

Mullerian dysgenesis with bilateral inguinal hernia
od: Rohan Khairatkar
Izdano: (2015-01-01)

Reliability of follicle-stimulating hormone measurements in serum
od: Kaaks Rudolf, i dr.
Izdano: (2003-06-01)